Copyright
©The Author(s) 1997. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Mar 15, 1997; 3(1): 43-46
Published online Mar 15, 1997. doi: 10.3748/wjg.v3.i1.43
Published online Mar 15, 1997. doi: 10.3748/wjg.v3.i1.43
Clinical observation of 125I-labeled anti-alpha fetoprotein antibody radioimmunotherapy in hepatocellular carcinoma
Ying-De Wu, Ke-Zeng Yang, You-Quan Gang, Xiang-Qun Song, Xiao-Hua Hu, Bing-Yan Huang, Department of Chemotherapy, Affiliated Cancer Hospital, Guangxi Medical University, Nanning 530021, Guangxi Province, China
De-Nan Zhou, Guangxi Cancer Institute, Nanning, Guangxi Province, China
Ying-De Wu, male, born on February 10, 1936, Fu Sui County, Zhuang nationality, graduated from the Faculty of Medicine, Guangxi Medical University, professor and chief physician of the Department of Medical Oncology; former head of the Department of Cancer Prevention and Director of the Department of Chemotherapy. Since 1980 he has been engaged mainly in the study of targeted therapy for hepatocellular carcinoma, radiation therapy and tumor chemotherapy, hepatocellular carcinoma research at state and provincial level, and has 31 papers published. At present, he is the Director of the Department of Immunity, Cancer Institute, Secretary General of Guangxi Anticancer Association and Executive Editor of the Journal of Chinese Medical Abstract — Oncology.
Author contributions: All authors contributed equally to the work.
Supported by Grants from Guangxi Commission of Science and Technology Research Items, No.900226.
Correspondence to: Dr. Ying-De Wu, Department of Chemotherapy, Affiliated Cancer Hospital, Guangxi Medical University, Nanning 530021, Guangxi Province, China
Telephone: +86-771-5313022-3137 (Home), 3051 (Office)
Received: August 29, 1996
Revised: December 1, 1996
Accepted: December 30, 1996
Published online: March 15, 1997
Revised: December 1, 1996
Accepted: December 30, 1996
Published online: March 15, 1997
Core Tip